Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

By Corey Langer, MD, IASLC Lung Cancer News Editor The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189, CheckMate 227...

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

By Fred R. Hirsch, MD, PhD Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of its refinement,...

PACIFIC Trial Leads to Durvalumab Approval in United States

The U.S. Food and Drug Administration approved durvalumab on February 16, 2018, for the treatment of patients with stage III NSCLC whose tumors are...

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

By Hossein Borghaei, MS, DO The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who...

Immunotherapy Adverse-Event Treatment Resource Guide

The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...

Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was focused and...

Exploring the Potential of Immuno-oncology Combination Therapy

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy, future articles...

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight...

PD-L1 Blueprint Project

By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of...

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...

By Melody Watson The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in NSCLC research...

Meeting News